Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by DiaMedica Therapeutics Inc.

< Previous 1 2 Next >
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Upcoming Conference Participation
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces $37.5 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Tickers DMAC
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.